# SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy

> **NCT00102726** · PHASE2 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 183 (actual)

## Conditions studied

- Thrombocytopaenia

## Interventions

- **DRUG:** SB497115
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00102726
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2007-02
- **Final completion:** 2007-02
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2017-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102726, "SB-497115 (Oral Thrombopoietin Receptor Agonist) Versus Placebo In Adult Cancer Patients Receiving Chemotherapy". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT00102726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*